Simon Dew
Corporate Officer/Principal bei RENEURON GROUP PLC
Profil
Simon Dew is currently the Chief Business Officer at ReNeuron Group Plc and a Member of the Royal Pharmaceutical Society of Great Britain.
Previously, he held positions as Vice President of Business and Corporate Development at Mereo BioPharma Group Plc, Vice President of Business Development at Evox Therapeutics Ltd., Vice President of Corporate Strategy at Gyroscope Therapeutics Ltd., and Vice President of Corporate Strategy and Business Development at Astellas Pharmaceuticals AG.
Aktive Positionen von Simon Dew
| Unternehmen | Position | Beginn |
|---|---|---|
| RENEURON GROUP PLC | Corporate Officer/Principal | 01.11.2022 |
Royal Pharmaceutical Society of Great Britain
 Royal Pharmaceutical Society of Great Britain Miscellaneous Commercial ServicesCommercial Services The Royal Pharmaceutical Society of Great Britain provides expertise and support to its member pharmacists. The private company is based in Great Britain. Alex MacKinnon has been the CEO of the British company since 2010. | Corporate Officer/Principal | - |
Ehemalige bekannte Positionen von Simon Dew
| Unternehmen | Position | Ende |
|---|---|---|
| MEREO BIOPHARMA GROUP PLC | Corporate Officer/Principal | - |
| Astellas Pharmaceuticals AG | Corporate Officer/Principal | - |
Evox Therapeutics Ltd.
 Evox Therapeutics Ltd. BiotechnologyHealth Technology Evox Therapeutics Ltd. develops and markets transformational therapeutics. The firm creates novel exosome-based biotherapeutics for the treatment of various severe diseases with limited options for patients and their families. The company was founded by Matthew Wood, Per Lundin, and Samir EL Andaloussi in 2016 and is headquartered in Oxford, the United Kingdom. | Corporate Officer/Principal | - |
Gyroscope Therapeutics Ltd.
 Gyroscope Therapeutics Ltd. BiotechnologyHealth Technology Gyroscope Therapeutics Ltd. operates as an ophthalmology firm. It develops a cutting edge, genetically-defined therapies for the treatment of eye diseases linked to an unbalanced complement system. The company was founded on April 18, 2016 and is headquartered in Stevenage, the United Kingdom. | Corporate Officer/Principal | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| RENEURON GROUP PLC | Health Technology |
| MEREO BIOPHARMA GROUP PLC | Health Technology |
| Private Unternehmen | 4 |
|---|---|
Royal Pharmaceutical Society of Great Britain
Royal Pharmaceutical Society of Great Britain Miscellaneous Commercial ServicesCommercial Services The Royal Pharmaceutical Society of Great Britain provides expertise and support to its member pharmacists. The private company is based in Great Britain. Alex MacKinnon has been the CEO of the British company since 2010. | Commercial Services |
Gyroscope Therapeutics Ltd.
Gyroscope Therapeutics Ltd. BiotechnologyHealth Technology Gyroscope Therapeutics Ltd. operates as an ophthalmology firm. It develops a cutting edge, genetically-defined therapies for the treatment of eye diseases linked to an unbalanced complement system. The company was founded on April 18, 2016 and is headquartered in Stevenage, the United Kingdom. | Health Technology |
| Astellas Pharmaceuticals AG | |
Evox Therapeutics Ltd.
Evox Therapeutics Ltd. BiotechnologyHealth Technology Evox Therapeutics Ltd. develops and markets transformational therapeutics. The firm creates novel exosome-based biotherapeutics for the treatment of various severe diseases with limited options for patients and their families. The company was founded by Matthew Wood, Per Lundin, and Samir EL Andaloussi in 2016 and is headquartered in Oxford, the United Kingdom. | Health Technology |